{"id":156420,"date":"2010-01-08T14:05:27","date_gmt":"2010-01-08T19:05:27","guid":{"rendered":"http:\/\/blogs.wsj.com\/health\/2010\/01\/08\/teva-and-the-narrowing-gap-between-generics-and-big-pharma\/"},"modified":"2010-01-08T14:05:27","modified_gmt":"2010-01-08T19:05:27","slug":"teva-and-the-narrowing-gap-between-generics-and-big-pharma","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/156420","title":{"rendered":"Teva and the Narrowing Gap Between Generics and Big Pharma"},"content":{"rendered":"

\"Teva\"Teva’s CEO said yesterday he expects his company’s revenues to double to $31 billion by 2015. The market apparently believed him: The company’s shares were up more than 3%<\/a> in U.S. trading this afternoon, to a 52-week high.<\/p>\n

Teva’s growth is the latest reminder of the way generic drugs and the companies that make them are changing the global pharma landscape. It’s no longer correct to think of generics manufacturers as scrappy little competitors nipping at the heels of big pharma.<\/p>\n

Teva’s market cap is around $50 billion — bigger than Eli Lilly’s<\/a> and comparable to Bristol-Myers Squibb’s<\/a>. (Of course, Teva trades at a much higher multiple than either Bristol or Lilly.)<\/p>\n

It’s not even right to think of Teva as a pure-play generics shop; a big chunk of its revenue comes from the patented multiple-sclerosis drug Copaxone, and the company plans to keep a sales mix of 70% generics and 30% branded drugs, Dow Jones Newswires reports<\/a>. Other big generics companies are also working on branded drugs; Dr. Reddy’s of India said<\/a> this week that an experimental diabetes drug it’s working on with a European partner reduced blood-sugar levels in a late-stage trial.<\/p>\n

At the same time, branded drug makers are moving further into the generics business. Pfizer made a deal<\/a> this week that adds to the list of off-patent drugs it’s selling in the U.S. GlaxoSmithKline<\/a> has cut its own generics deals, Sanofi-Aventis<\/a> has bought some generics makers outright and Merck<\/a> recently set up a unit to sell generic copies of biotech drugs.<\/p>\n

<\/img><\/a>
\n<\/img><\/a><\/p>\n

\n<\/img><\/a> <\/img><\/a> <\/img><\/a> <\/img><\/a> <\/img><\/a>\n<\/div>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Teva’s CEO said yesterday he expects his company’s revenues to double to $31 billion by 2015. The market apparently believed him: The company’s shares were up more than 3% in U.S. trading this afternoon, to a 52-week high. Teva’s growth is the latest reminder of the way generic drugs and the companies that make them […]<\/p>\n","protected":false},"author":650,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-156420","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/156420","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/650"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=156420"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/156420\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=156420"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=156420"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=156420"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}